Press Releases Items Per Page 102550 News Category FinancialGeneral Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Nektar Therapeutics Presents Clinical Data from Phase 3 SUMMIT-07 Study of NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2017 PAINWeek® Sep 06, 2017 Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2017 Morgan Stanley Global Healthcare Conference in New York City Sep 06, 2017 Nektar Therapeutics to Present Clinical Data from Phase 3 SUMMIT-07 Study of NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at PAINWeek® Aug 30, 2017 Nektar Therapeutics Reports Financial Results for the Second Quarter of 2017 Aug 08, 2017 Nektar to Announce Financial Results for the Second Quarter of 2017 on Tuesday, August 8, 2017, After Close of U.S.-Based Financial Markets Aug 02, 2017 Lilly and Nektar Therapeutics Announce Alliance to Develop and Commercialize NKTR-358, A Novel Autoimmune Therapy Jul 24, 2017 Nektar Announces Topline Data from Human Abuse Potential Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain Jul 18, 2017 Nektar Presents New Preclinical Data for NKTR-358, a First-in-Class Regulatory T Cell Stimulator, at 13th World Congress of Inflammation in London Jul 10, 2017 Nektar to Webcast Presentation at Jefferies 2017 Global Healthcare Conference in New York City Jun 06, 2017 Nektar Presents New Clinical Data from Two Studies of NKTR-214, a CD122-Biased Agonist, at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting Jun 05, 2017 Pagination First page « first Previous page ‹ previous … Page 16 Page 17 Page 18 Page 19 Current page 20 Page 21 Page 22 Page 23 Page 24 … Next page next › Last page last »